ABT-546 NEW
| Price | $1520 | $1980 | $2500 |
| Package | 25mg | 50mg | 100mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-08-21 |
Product Details
| Product Name: ABT-546 | CAS No.: 212481-66-8 |
| Supply Ability: 10g | Release date: 2025/08/21 |
Product Introduction
Bioactivity
| Name | ABT-546 |
| Description | ABT-546 (A-216546) is a potent, highly selective, and active endothelin ETA receptor antagonist with a Ki of 0.46 nM for [125I]endothelin-1 binding to cloned human endothelin ETA. |
| Animal Research | Animal Model: Male Sprague-Dawley rats (250-350 g) induced with endothelin-1. Dosage: 0.1 mg/kg, 1 mg/kg, 10 mg/kg, 30 mg/kg, 100 mg/kg. Administration: p.o.; for 1 hour or 4 hours |
| In vitro | ABT-546 is ＞25,000-fold more selective for the ETA receptor than for the ETB receptor. ABT-546 blocks endothelin-1-induced arachidonic acid release and phosphatidylinositol hydrolysis (IC50s: 0.59 nM and 3 nM). ABT-546 effectively inhibits specific I endothelin-1 binding to endothelin ETA receptor in membranes prepared from rat pituitary MMQ cells (IC50: 0.56 nM). In membranes prepared from CHO cells stably transfected with the human endothelin ETA and ETB receptors, ABT-546 again effectively inhibits specific [125I]endothelin-1 binding to endothelin ETA receptor (IC50: 0.49 nM), but is less effective in inhibiting specific [125I]endothelin-3 binding to endothelin ETB receptor (IC50: 15,400 nM). In isolated vessels, ABT-546 inhibits endothelin ETA receptor-mediated endothelin-1-induced vasoconstriction, and endothelin ETB receptor-mediated sarafotoxin 6c-induces vasoconstriction with pA2 of 8.29 and 4.57, respectively. |
| In vivo | ABT-546 (0-100 mg/kg; p.o.; for 1 hour or 4 hours; male Sprague-Dawley rats) treatment dose-dependently blocks the endothelin-1-induced pressor response in conscious rats. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Keywords | A216546 | ABT-546 | ABT546 | A 216546 | ABT 546 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $3.00/25KG |
VIP1Y
|
ZHENGZHOU JIUYI TIME NEW MATERIALS CO,.LTD
|
2025-07-05 | |
| $0.00/1kg |
VIP2Y
|
Shandong Hanjiang Chemical Co., Ltd
|
2024-01-19 | |
| $2500.00/100mg |
VIP2Y
|
TargetMol Chemicals Inc.
|
2025-07-16 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY